GC Biopharma has surpassed 500 billion won in quarterly sales for the first time since its founding.
GC Biopharma reported on the 1st that its consolidated financial statement for the second quarter recorded 500.3 billion won, an increase of 19.9% compared to the same period last year. During the same period, operating profit rose 55.1% to 27.4 billion won. Net profit recorded 32.7 billion won, marking a return to profitability.
The company noted that it achieved the largest quarterly sales in history by expanding its global business in key items. In particular, sales of plasma fractionation products reached 152 billion won, with substantial growth in sales of 'Aliclo', solidifying its position as a core growth driver. Aliclo achieved cumulative sales of 100 billion won last month, just one year after its launch in the U.S. market.
Sales of vaccine products reached 102.9 billion won, prescription drugs 106.1 billion won, and over-the-counter drugs and consumer healthcare recorded sales of 30.8 billion won. The company explained that the varicella vaccine has established itself as a new growth driver, contributing to both expansion and improved profitability, while the increase in overseas sales of the prescription drug Hunterase led the growth.
The company stated that its subsidiaries also showed stable trends. GC Cell recorded sales of 43 billion won, reducing the operating loss compared to the previous quarter. GC Biopharma MS and GC Biopharma Wellbeing also generated sales growth and favorable revenue thanks to the strong performance of their respective core businesses in diagnostic kits and injectables.
A representative from GC Biopharma commented, "Despite the forecast of economic uncertainty in the second half of the year, the positive performance trends in the core institutional sectors will continue."